Scott L. Burrows
Chief Financial Officer at Spyre Therapeutics; Chief Financial Officer at Arcutis Biotherapeutics. Based in Waltham, Massachusetts.
- Rank
- 9208th of 14,644
- Companies held
- 2
- Largest holding
- SYRE, 82.9% of total
- Latest SEC filing
- Oct 1, 2026
What the $9.4M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Spyre Therapeutics SYRE Common Stock | Directly | 79,762 | $97.63 | $7.8M | 82.9% | Form 4, Oct 1, 2026 |
| Arcutis Biotherapeutics ARQT Common Stock | Directly | 59,115 | $27.17 | $1.6M | 17.1% | Form 4, Mar 6, 2023 |
Share counts are the amounts Scott L. Burrows reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Sold | SYRE | 600 | $89.07 | $53K | View |
| Oct 1, 2026 | Sold | SYRE | 1,500 | $90.27 | $135K | View |
| Oct 1, 2026 | Sold | SYRE | 2,100 | $91.92 | $193K | View |
| Oct 1, 2026 | Sold | SYRE | 3,071 | $92.95 | $285K | View |
| Oct 1, 2026 | Sold | SYRE | 229 | $93.57 | $21K | View |
| Sep 30, 2026 | Sold | SYRE | 17,500 | $89.89 | $1.6M | View |
| Sep 2, 2026 | Sold | SYRE | 18,232 | $89.35 | $1.6M | View |
| Sep 1, 2026 | Sold | SYRE | 200 | $89.04 | $18K | View |
| Sep 1, 2026 | Sold | SYRE | 2,016 | $88.03 | $177K | View |
| Sep 1, 2026 | Sold | SYRE | 900 | $86.25 | $78K | View |
| Sep 1, 2026 | Sold | SYRE | 4,384 | $87.11 | $382K | View |
| Aug 3, 2026 | Sold | SYRE | 2,300 | $96.30 | $221K | View |
| Aug 3, 2026 | Sold | SYRE | 5,100 | $95.21 | $486K | View |
| Aug 3, 2026 | Sold | SYRE | 100 | $97.10 | $10K | View |
| Jul 1, 2026 | Sold | SYRE | 5,775 | $87.55 | $506K | View |
| Jul 1, 2026 | Sold | SYRE | 1,725 | $88.37 | $152K | View |
| Jun 25, 2026 | Sold | SYRE | 5,000 | $87.12 | $436K | View |
| Jun 25, 2026 | Sold | SYRE | 10,000 | $87.14 | $871K | View |
| Jun 1, 2026 | Sold | SYRE | 3,100 | $72.06 | $223K | View |
| Jun 1, 2026 | Sold | SYRE | 2,599 | $70.77 | $184K | View |
| Jun 1, 2026 | Sold | SYRE | 1,801 | $69.75 | $126K | View |
| May 1, 2026 | Sold | SYRE | 12,500 | $71.37 | $892K | View |
| Apr 1, 2026 | Sold | SYRE | 6,200 | $49.21 | $305K | View |
| Apr 1, 2026 | Sold | SYRE | 1,300 | $49.98 | $65K | View |
| Mar 3, 2026 | Sold | SYRE | 200 | $41.66 | $8K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 9205 | Brian O. Casey CEO, Westwood Holdings Group. Dallas, TX | $9.4M |
| 9206 | Philip Riley CFO & EVP STRATEGY, Riley Exploration Permian. Oklahoma City, OK | $9.4M |
| 9207 | Alton Shader Chief Executive Officer, Sotera Health. Broadview Heights, OH | $9.4M |
| 9208 | Scott L. Burrows Chief Financial Officer, Spyre Therapeutics. Waltham, MA | $9.4M |
| 9209 | Robert A. Schriesheim Interim CFO, Skyworks Solutions. Deerfield, IL | $9.4M |
| 9210 | Lisa D. Earnhardt EVP AND GROUP PRESIDENT, Abbott Laboratories. Abbott Park, IL | $9.4M |
| 9211 | James K. Lee Chief Operating Officer, Bentley Systems. Exton, PA | $9.4M |
Other Spyre Therapeutics insiders
All SYRE insiders- Cameron Turtle$52.5MChief Executive Officer. #2428 overall
- Michael Thomas Henderson$6.7MDirector. #11774 overall
- Marcio Souza$351KDirector. #5469 overall
Questions
How much stock does Scott L. Burrows own?
Scott L. Burrows holds $9,393,319 in listed stock based on SEC filings and current prices, mostly Spyre Therapeutics (SYRE). That ranks 9208th on the Stock Rich List.
Is this Scott L. Burrows's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Scott L. Burrows last buy or sell stock?
The most recent open-market trade on file is a sale of 600 SYRE shares on Oct 1, 2026 at $89.07.